comparemela.com

Latest Breaking News On - Kimn chi - Page 1 : comparemela.com

Olaparib combo improves PFS in metastatic prostate cancer

Frontline olaparib plus abiraterone/prednisone combo improves survival in patients with metastatic castration-resistant prostate cancer.

United kingdomBritish columbiaUnited statesMaha hussainKimn chiRoberth lurie comprehensive cancer centerProstate cancer working groupUniversity of british columbiaComprehensive cancer centerBoth dr hussainProstate carcinomaAlignant prostate neoplasmProstate cancerAncer of the prostateBreast cancerAlignant breast neoplasm

Small PFS Gain in Metastatic Prostate Cancer With TKI, ICI

Men with metastatic castration-resistant prostate cancer had a slight but significant improvement in progression-free survival with a TKI plus immunotherapy vs hormonal therapy.

United statesUniversity of utahUnited kingdomSalt lake cityBritish columbiaKimn chiNeeraj agarwalKim chiXin gaoProstate cancer working groupUniversity of british columbiaCancer centerHuntsman cancer instituteSalt lakeMass general cancer centerProstate carcinoma

Cabozantinib Plus Atezolizumab Delays Progression in mCRPC

Combination improved PFS versus more hormonal therapy, but control arm questioned

United statesUnited kingdomBritish columbiaSalt lake cityUniversity of utahMike bassettNeeraj agarwalKimn chiBritish columbia cancer agencyHuntsman cancer instituteGenitourinary cancers

Olaparib-Abiraterone in Biomarker-Selected mCRPC Tops Each Agent Alone

In small first-line trial, PFS more than doubled with combination

United statesBritish columbiaUnited kingdomMaha hussainMike bassettKimn chiNorthwestern university feinberg school of medicineBritish columbia cancer agencyNorthwestern universityFeinberg schoolGenitourinary cancers symposium

Dr Chi on the MAGNITUDE Trial of Niraparib Plus Abiraterone in BRCA-Mutated mCRPC

Kim N. Chi, MD, FRCPC, discusses data from the updated and final analysis of the phase 3 MAGNITUDE trial in BRCA-positive metastatic castration-resistant prostate cancer.

United kingdomKimn chiUniversity of british columbiaDivision of medical oncologyMedical oncologyBritish columbiaProstate cancerPhase 3 magnitude nct03748641

vimarsana © 2020. All Rights Reserved.